Get the App

Nonin, Qualcomm Life Collaborate on New Development

Manufacturing Group | December 6, 2012

Pulse Oximetry for the 2net Platform for Wireless Health Solutions

Officials at Nonin Medical Inc., the inventor of finger-pulse oximetry and a leader in noninvasive medical monitoring, announce that the company's Onyx II Model 9560 Fingertip Pulse Oximeter is now compatible with the 2net Platform for wireless health solutions. Developed by Qualcomm Life Inc., a subsidiary of Qualcomm Incorporated, the 2net Platform is a cloud-based system designed to be universally interoperable with different medical devices and applications, enabling end-to-end wireless connectivity while allowing medical device users and their physicians or caregivers to easily access biometric data. The connection between the 2net Hub and Nonin is made via a Continua-compliant Bluetooth wireless technology protocol.

"As a leader in developing non-invasive monitoring devices, we are proud to be the first company to offer a pulse oximeter solution that seamlessly integrates into the 2net Platform," says Mark VanderWerf, vice president-ehealth for Nonin Medical. "The clinical quality data provided by the Onyx II through the 2net Hub and Platform will enable clinicians to remotely monitor patients with chronic diseases such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF) or asthma."

The announcement was made during the Fourth Annual mHealth Summit in Washington, D.C., the largest event of its kind that brings together leaders in government, the private sector, industry, academia, providers and not-for-profit organizations throughout healthcare to advance collaboration in the use of wireless technology to improve patient outcomes.

"We are pleased to have Nonin Medical incorporate the 2net Platform into their product offering," says Rick Valencia, vice president and general manager of Qualcomm Life. "Nonin's leadership in their device offerings for patients with COPD, CHF or asthma will broaden our portfolio of remote monitoring options for users with these conditions and we look forward to seeing the improvement of overall clinical outcomes."

You May Also Like

comments powered by Disqus
x